Table 3 The relationship between CD44v6 and integrin-β1 protein expression and clinical pathological features of patients with PC
Pathological features | N | CD44v6 protein expression | P value | Integrin-β1 protein expression | P value | ||
|---|---|---|---|---|---|---|---|
High | Low | High | Low | ||||
Sex | 0.201 | 0.269 | |||||
Male | 27 | 14 (51.9%) | 13 (48.1%) | 15 (55.6%) | 12 (44.4%) | ||
Female | 27 | 10 (37.0%) | 17 (63.0%) | 12 (44.4%) | 15 (55.6%) | ||
Age | 0.856 | 0.189 | |||||
≤60 | 24 | 11 (45.8%) | 13 (54.2%) | 14 (58.3%) | 10 (41.7%) | ||
>60 | 30 | 13 (43.3%) | 17 (56.7%) | 13 (43.3%) | 17 (56.7%) | ||
Tumor location | 0.086 | 0.378 | |||||
Head and body PC | 34 | 12 (35.3%) | 22 (64.7%) | 16 (47.1%) | 18 (52.9%) | ||
Tail PC | 20 | 12 (60.0%) | 8 (40.0%) | 11 (55.0%) | 9 (45.0%) | ||
Clinical stages | 0.046 | 0.019 | |||||
I+II | 21 | 6 (28.6%) | 15 (71.4%) | 6 (31.6%) | 13 (68.4%) | ||
III+IV | 33 | 18 (54.5%) | 15 (45.5%) | 21 (60.0%) | 14 (40.0%) | ||
Tumor differentiation | 0.037 | 0.038 | |||||
Poorly and moderately | 33 | 10 (30.3%) | 23 (69.7%) | 12 (36.4%) | 21 (63.6%) | ||
Highly | 21 | 14 (66.7%) | 7 (33.3%) | 15 (71.4%) | 6 (28.6%) | ||
Tumor size (diameter) | 0.112 | 0.154 | |||||
≤4 cm | 25 | 8 (32.0%) | 18 (68.0%) | 11 (44.0%) | 14 (56.0%) | ||
>4 cm | 29 | 16 (55.2%) | 12 (44.8%) | 16 (55.2%) | 13 (44.8%) | ||
LNM | 0.035 | 0.017 | |||||
Negative | 20 | 5 (25.0%) | 15 (75.0%) | 7 (30.4%) | 16 (69.6%) | ||
Positive | 34 | 19 (55.9%) | 15 (44.1%) | 20 (69.0%) | 9 (31.0%) | ||
Liver metastasis | 0.013 | 0.029 | |||||
Negative | 24 | 5 (20.8%) | 19 (79.2%) | 7 (29.2%) | 17 (71.8%) | ||
Positive | 30 | 19 (63.3%) | 11 (36.7%) | 20 (66.7%) | 10 (33.3%) | ||
CA199(U/ml) | 0.187 | 0.354 | |||||
≤1000 | 18 | 6 (33.3%) | 12 (66.7%) | 8 (44.4%) | 10 (55.6%) | ||
>1000 | 36 | 18 (50.0%) | 18 (50.0%) | 19 (52.8%) | 17 (47.2%) | ||
KPS | 0.233 | 0.176 | |||||
≤80 | 25 | 13 (52.0%) | 12 (48.0%) | 15 (60.0%) | 10 (40.0%) | ||
>80 | 29 | 11 (37.9%) | 18 (62.1%) | 12 (41.4%) | 17 (58.6%) | ||